Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
This article was originally published in The Gray Sheet
Executive Summary
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
You may also be interested in...
Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report
A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.
Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report
A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.
Personalized Medicine Does Not Fit In FDA's Current Scheme, Experts Say
"FDA has signaled several times that they are considering regulation of the space," says Personalized Medicine Coalition CEO Rosenkrans. But, "they aren't quite sure how to do it."